Log in

NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

$0.73
+0.01 (+1.38 %)
(As of 12/8/2019 05:01 AM ET)
Today's Range
$0.73
Now: $0.73
$0.76
50-Day Range
$0.72
MA: $0.84
$1.06
52-Week Range
$0.71
Now: $0.73
$4.32
Volume89,845 shs
Average Volume427,547 shs
Market Capitalization$26.30 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.48
Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.07 million
Book Value($0.14) per share

Profitability

Net Income$-24,160,000.00

Miscellaneous

Employees8
Market Cap$26.30 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.


Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.11). View Innovate Biopharmaceuticals' Earnings History.

When is Innovate Biopharmaceuticals' next earnings date?

Innovate Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Innovate Biopharmaceuticals.

What price target have analysts set for INNT?

1 analysts have issued 1-year target prices for Innovate Biopharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Innovate Biopharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 1,264.3% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.

What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.

Has Innovate Biopharmaceuticals been receiving favorable news coverage?

Media coverage about INNT stock has trended somewhat positive on Sunday, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Innovate Biopharmaceuticals.

Are investors shorting Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,440,000 shares, an increase of 49.1% from the October 31st total of 965,800 shares. Based on an average trading volume of 171,700 shares, the short-interest ratio is presently 8.4 days. Currently, 6.3% of the company's shares are short sold. View Innovate Biopharmaceuticals' Current Options Chain.

Who are some of Innovate Biopharmaceuticals' key competitors?

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), Axsome Therapeutics (AXSM), Alibaba Group (BABA), Iterum Therapeutics (ITRM), Momo (MOMO), AcelRx Pharmaceuticals (ACRX), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL) and Progenics Pharmaceuticals (PGNX).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the folowing people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

Who are Innovate Biopharmaceuticals' major shareholders?

Innovate Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sabby Management LLC (3.48%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.

Which major investors are selling Innovate Biopharmaceuticals stock?

INNT stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Innovate Biopharmaceuticals.

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $0.73.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $26.30 million and generates $4.07 million in revenue each year. The company earns $-24,160,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe.View Additional Information About Innovate Biopharmaceuticals.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]


MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Dogs of the Dow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel